(4-氯-3-硝基苯基)(4-吗啉基)甲酮 | 174482-89-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-氯-3-硝基苯基)(4-吗啉基)甲酮
• 中文别名: 4-(4-氯-3-硝基苯甲酰)吗啉；(4-氯-3-硝基苯基)(吗啉-4-基)甲酮
• 英文名称: (4-chloro-3-nitrophenyl)(morpholino)methanone
• 英文别名: 4-chloro-3-nitrobenzoic acid morpholide；4-(4-Chloro-3-nitrobenzoyl)morpholine；(4-chloro-3-nitrophenyl)-morpholin-4-ylmethanone
• CAS: 174482-89-4
• 化学式: C₁₁H₁₁ClN₂O₄
• mdl: MFCD00583780
• 分子量: 270.672
• InChiKey: JFGITFUPSIAISG-UHFFFAOYSA-N

物化性质

• 沸点：
  463.6±45.0 °C(Predicted)
• 密度：
  1.429±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  75.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (4-氯-3-硝基苯基)(4-吗啉基)甲酮 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 [4-[4-(Benzotriazole-1-carbonyl)piperazin-1-yl]-3-nitrophenyl]-morpholin-4-ylmethanone
  参考文献：
  名称：

  Development and characterization of endocannabinoid hydrolases FAAH and MAGL inhibitors bearing a benzotriazol-1-yl carboxamide scaffold

  摘要：

  A series of (1H-benzo[d][1,2,3]triazol-1-yl)(4-benzylpiperazin-1-yl)methanones and of (1H-benzo[d] [1,2,3]triazol-1-yl)(4-phenylpiperazin-1-yl)methanones has been prepared and tested on human fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). In the benzylpiperazinyl series, compound 29 (ML30) exhibited an IC50 value of 0.54 nM on MAGL, combined with a 1000-fold selectivity versus FAAH, while compounds 11 and 16 acted as potent dual FAAH-MAGL inhibitors (IC50 <10 nM). In the phenylpiperazinyl series, compounds 37, 38, 42, and 43 displayed IC50 values against MAGL in the nanomolar range, whilst being between one and two orders of magnitude less potent on the FAAH, while compounds 31 and 32 were potent FAAH inhibitors (IC50 <20 nM) and over 12-fold selective versus MAGL. The key structural determinants driving the structure-activity relationships were explored by the minimization of the inhibitors inside the active site of both enzymes. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.09.011
• 作为产物：
  描述：

  4-氯-3-硝基苯甲酸 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 生成 (4-氯-3-硝基苯基)(4-吗啉基)甲酮
  参考文献：
  名称：

  Development and characterization of endocannabinoid hydrolases FAAH and MAGL inhibitors bearing a benzotriazol-1-yl carboxamide scaffold

  摘要：

  A series of (1H-benzo[d][1,2,3]triazol-1-yl)(4-benzylpiperazin-1-yl)methanones and of (1H-benzo[d] [1,2,3]triazol-1-yl)(4-phenylpiperazin-1-yl)methanones has been prepared and tested on human fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). In the benzylpiperazinyl series, compound 29 (ML30) exhibited an IC50 value of 0.54 nM on MAGL, combined with a 1000-fold selectivity versus FAAH, while compounds 11 and 16 acted as potent dual FAAH-MAGL inhibitors (IC50 <10 nM). In the phenylpiperazinyl series, compounds 37, 38, 42, and 43 displayed IC50 values against MAGL in the nanomolar range, whilst being between one and two orders of magnitude less potent on the FAAH, while compounds 31 and 32 were potent FAAH inhibitors (IC50 <20 nM) and over 12-fold selective versus MAGL. The key structural determinants driving the structure-activity relationships were explored by the minimization of the inhibitors inside the active site of both enzymes. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.09.011

文献信息

• Benzene derivatives and pharmaceutical composition
  申请人：Kureha Chemical Industry Co., Ltd.

  公开号：US05696118A1

  公开（公告）日：1997-12-09

  A benzene derivative of the formula (I): ##STR1## wherein R.sup.1 is hydrogen, C.sub.1-6 -alkyl, C.sub.1-6 -haloalkyl, --NH.sub.2, --NHR.sup.21 ; R.sup.2 is hydroxyl, --OR.sup.22, three- to seven-membered saturated cycloaliphatic amino optionally interrupted by one or more nitrogen, oxygen or sulfur atoms, --NHR.sup.23, --N(R.sup.24).sub.2, --NH.sub.2 ; R.sup.4 is hydrogen, C.sub.1-6 -alkyl, or --C(.dbd.O)R.sup.25 ; R.sup.7 is --CO--, --SO.sub.2 --; R.sup.8 is --CO--, single bond; R.sup.12 is --R.sup.11 --R.sup.5 ; R.sup.11 is --N(R.sup.5)--, --NH--, --O--, --N(R.sup.26)--, --N(C(.dbd.O)R.sup.27)--, --N(C(.dbd.O)NH.sub.2)--, --N(C(.dbd.O)NHR.sup.28)--; R.sup.13 is hydrogen, C.sub.1-6 -alkyl, C.sub.1-6 -haloalkyl, --NHC(.dbd.O)(CH.sub.2).sub.m C.sub.6 H.sub.5, --NHC(.dbd.O)R.sup.29, --NHC(.dbd.O)CH(C.sub.6 H.sub.5).sub.2, --NH.sub.2, --NHR.sup.30, --(CH.sub.2).sub.n C.sub.6 H.sub.5 ; Z is C, CH, N; A is CH, N; R.sup.5 is hydrogen, --CH.sub.2 C.sub.6 H.sub.4 COOH, --CH.sub.2 C.sub.6 H.sub.4 COOR.sup.31, --CH.sub.2 C.sub.6 H.sub.4 OH, --CH.sub.2 C.sub.6 H.sub.4 OR.sup.32, --CH.sub.2 C.sub.6 H.sub.4 NH.sub.2, --CH.sub.2 C.sub.6 H.sub.4 N(R.sup.33).sub.2, --CH.sub.2 C.sub.6 H.sub.4 -azole, --CH.sub.2 C.sub.6 H.sub.4 NHR.sup.34, --CH.sub.2 C.sub.6 H.sub.4 C.sub.6 H.sub.4 R.sup.14 ; R.sup.14 is azole, --COOH; R.sup.21 to R.sup.34 are independently C.sub.1-6 -alkyl or C.sub.1-6 -haloalkyl; m is 0 to 6; n is 0 to 6; t is 0 or 1, with the proviso that when Z is N, R.sup.5 is hydrogen, --CH.sub.2 C.sub.6 H.sub.4 COOH, --CH.sub.2 C.sub.6 H.sub.4 COOR.sup.31, --CH.sub.2 C.sub.6 H.sub.4 OH, --CH.sub.2 C.sub.6 H.sub.4 OR.sup.32, --CH.sub.2 C.sub.6 H.sub.4 NH.sub.2, --CH.sub.2 C.sub.6 H.sub.4 N(R.sup.33).sub.2, --CH.sub.2 C.sub.6 H.sub.4 -azole, or --CH.sub.2 C.sub.6 H.sub.4 NHR.sup.34, or a salt thereof, and a pharmaceutical composition comprising said benzene derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier are disclosed.

  一种化学式为(I)的苯衍生物：其中R.sup.1是氢，C.sub.1-6-烷基，C.sub.1-6-卤代烷基，-NH.sub.2，-NHR.sup.21；R.sup.2是羟基，-OR.sup.22，三至七元饱和环脂肪族氨基，可选地由一个或多个氮、氧或硫原子中断，-NHR.sup.23，-N(R.sup.24).sub.2，-NH.sub.2；R.sup.4是氢，C.sub.1-6-烷基，或-C(.dbd.O)R.sup.25；R.sup.7是-CO-，-SO.sub.2-；R.sup.8是-CO-，单键；R.sup.12是-R.sup.11-R.sup.5；R.sup.11是-N(R.sup.5)-，-NH-，-O-，-N(R.sup.26)-，-N(C(.dbd.O)R.sup.27)-，-N(C(.dbd.O)NH.sub.2)-，-N(C(.dbd.O)NHR.sup.28)-；R.sup.13是氢，C.sub.1-6-烷基，C.sub.1-6-卤代烷基，-NHC(.dbd.O)(CH.sub.2).sub.mC.sub.6H.sub.5，-NHC(.dbd.O)R.sup.29，-NHC(.dbd.O)CH(C.sub.6H.sub.5).sub.2，-NH.sub.2，-NHR.sup.30，-(CH.sub.2).sub.nC.sub.6H.sub.5；Z是C，CH，N；A是CH，N；R.sup.5是氢，-CH.sub.2C.sub.6H.sub.4COOH，-CH.sub.2C.sub.6H.sub.4COOR.sup.31，-CH.sub.2C.sub.6H.sub.4OH，-CH.sub.2C.sub.6H.sub.4OR.sup.32，-CH.sub.2C.sub.6H.sub.4NH.sub.2，-CH.sub.2C.sub.6H.sub.4N(R.sup.33).sub.2，-CH.sub.2C.sub.6H.sub.4-唑，-CH.sub.2C.sub.6H.sub.4NHR.sup.34，-CH.sub.2C.sub.6H.sub.4C.sub.6H.sub.4R.sup.14；R.sup.14是唑，-COOH；R.sup.21到R.sup.34独立地是C.sub.1-6-烷基或C.sub.1-6-卤代烷基；m为0至6；n为0至6；t为0或1，但当Z为N时，R.sup.5是氢，-CH.sub.2C.sub.6H.sub.4COOH，-CH.sub.2C.sub.6H.sub.4COOR.sup.31，-CH.sub.2C.sub.6H.sub.4OH，-CH.sub.2C.sub.6H.sub.4OR.sup.32，-CH.sub.2C.sub.6H.sub.4NH.sub.2，-CH.sub.2C.sub.6H.sub.4N(R.sup.33).sub.2，-CH.sub.2C.sub.6H.sub.4-唑，或-CH.sub.2C.sub.6H.sub.4NHR.sup.34，或其盐，以及包括所述苯衍生物或其药学上可接受的盐的药物组合物和药学上可接受的载体。
• Design, synthesis and assay of 2-(4-phenylpiperazin-1-yl)pyrimidine-5- carboxamide derivatives as acetylcholinesterase inhibitors
  作者：Ben-Ben Wei、Chuang Han、Pan-Pan Shang、Xin-Yuan Guo、Li-Gai Bai、Zheng-Yue Ma

  DOI：10.1007/s00044-022-02949-0

  日期：2022.11

  2-(4-phenylpiperazin-1-yl)pyrimidine-5-carboxamide derivatives as acetylcholinesterase inhibitors (AChEIs) were designed and synthesized for the treatment of Alzheimer’s disease (AD). Their bioactivities were evaluated by the Ellman’s method, and the results showed that most of synthesized compounds displayed moderate acetylcholinesterase inhibitory activities in vitro. Among them, compound 6g exhibited the most potent

  一系列2-(4-苯基哌嗪-1-基)嘧啶-5-甲酰胺衍生物作为乙酰胆碱酯酶抑制剂(AChEIs) 被设计和合成用于治疗阿尔茨海默病(AD)。采用Ellman方法评价它们的生物活性，结果表明大多数合成的化合物在体外显示出中等的乙酰胆碱酯酶抑制活性。其中，化合物6g对AChE的抑制活性最强，IC 50为0.90 μM，对丁酰胆碱酯酶(BuChE)的抑制活性较差，IC 50为7.53 μM，表明化合物6g是选择性AChE抑制剂，化合物6g化合物6g与 AChE 和 BuChE的分子对接研究证实了其作为选择性 AChE 抑制剂。此外，通过动力学研究分析了化合物6g对AChE的抑制作用机制，结果表明化合物6g是竞争性抑制和非竞争性抑制的混合型抑制剂。综上所述，化合物6g可作为开发 AD 药物的先导化合物。
• Fragment-based design, synthesis and biological evaluation of theophylline derivatives as ATAD2 inhibitors in BT-549 cells
  作者：Dahong Yao、Jieshu You、Xuetao Yang、Jin Zhang、Xiaojun Yao

  DOI：10.1080/14756366.2023.2242601

  日期：2023.12.31

  this study, we design a series of theophylline derivatives as novel ATAD2 inhibitors through fragment-based screening and scaffold growth strategy. A novel potent ATAD2 inhibitor (compound 19f) is discovered with an IC50 value of 0.27 μM against ATAD2, which adopts a combination of classic and atypical binding mode. Additionally, compound 19f could impede ATAD2 activity and c-Myc activation, induced significant

  摘要 ATP酶家族AAA结构域蛋白2（ATAD2）因其致癌表观遗传修饰与癌细胞增殖、凋亡、迁移和耐药性密切相关，已成为热门的抗癌药物靶点。在本研究中，我们通过基于片段的筛选和支架生长策略设计了一系列茶碱衍生物作为新型ATAD2抑制剂。我们发现了一种新型有效的 ATAD2 抑制剂（化合物19f） ，其针对 ATAD2的 IC 50值为 0.27 μM，采用经典和非典型结合模式的组合。此外，化合物19f可以阻碍 ATAD2 活性和 c-Myc 激活，诱导显着的细胞凋亡，并在 BT-549 细胞中显示出抗迁移作用。总的来说，这些结果为开发用于三阴性乳腺癌（TNBC）治疗的新型有效 ATAD2 抑制剂提供了新的启示。
• Development and characterization of endocannabinoid hydrolases FAAH and MAGL inhibitors bearing a benzotriazol-1-yl carboxamide scaffold
  作者：Ludovica Morera、Geoffray Labar、Giorgio Ortar、Didier M. Lambert

  DOI：10.1016/j.bmc.2012.09.011

  日期：2012.11

  A series of (1H-benzo[d][1,2,3]triazol-1-yl)(4-benzylpiperazin-1-yl)methanones and of (1H-benzo[d] [1,2,3]triazol-1-yl)(4-phenylpiperazin-1-yl)methanones has been prepared and tested on human fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). In the benzylpiperazinyl series, compound 29 (ML30) exhibited an IC50 value of 0.54 nM on MAGL, combined with a 1000-fold selectivity versus FAAH, while compounds 11 and 16 acted as potent dual FAAH-MAGL inhibitors (IC50 <10 nM). In the phenylpiperazinyl series, compounds 37, 38, 42, and 43 displayed IC50 values against MAGL in the nanomolar range, whilst being between one and two orders of magnitude less potent on the FAAH, while compounds 31 and 32 were potent FAAH inhibitors (IC50 <20 nM) and over 12-fold selective versus MAGL. The key structural determinants driving the structure-activity relationships were explored by the minimization of the inhibitors inside the active site of both enzymes. (C) 2012 Elsevier Ltd. All rights reserved.